Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.3800
+0.0267 (7.56%)
At close: Nov 3, 2026, 4:00 PM EST
0.3800
0.00 (0.00%)
Pre-market: Nov 4, 2026, 5:00 AM EST
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $166.13K in the quarter ending June 30, 2026, with 1.98% growth. This brings the company's total for the last twelve months to $721.39K, down -28.12% year-over-year. In the year 2025, Co-Diagnostics had annual revenue of $622.49K, down -84.10%. That makes Co-Diagnostics the 44,100th largest company in the world by revenue and 6,213th in the United States.
Revenue (ttm)
$721.39K
Revenue Growth
-28.12%
P/S Ratio
4.19
Revenue / Employee
$6,273
Employees
115
Market Cap
3.02M
Revenue by Geography
- United States 581.55K 93.4%
- Rest of World 40.94K 6.6%
Fiscal year ended Dec 31, 2025 See the full Co-Diagnostics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 622.49K | -3.29M | -84.10% |
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | 214.97K | 175.06K | 438.63% |
| Dec 31, 2018 | 39.91K | 32.25K | 420.90% |
| Dec 31, 2017 | 7.66K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 10.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baird Medical Investment Holdings | 24.49M |
| WORK Medical Technology Group LTD | 10.72M |
| Nuwellis | 9.01M |
| INVO Fertility | 7.53M |
| IceCure Medical | 3.95M |
| VolitionRx | 2.46M |
| 20/20 Biolabs | 2.04M |
| Phaos Technology Holdings (Cayman) Limited | 103.68K |
CODX News
- 5 days ago - Co-Diagnostics JV’s Saragene biopsy test shows efficacy in published study - TheFly
- 5 days ago - Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast - PRNewsWire
- 5 days ago - Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test - PRNewsWire
- 7 days ago - Co-Diagnostics JV completes study of CoSara PCR MTB test, submits for clearance - TheFly
- 7 days ago - Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India - PRNewsWire
- 8 days ago - Co-Diagnostics Proxy statement: Proxy filing - Filings
- 14 days ago - Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum - PRNewsWire
- 18 days ago - Co-Diagnostics Proxy statement: Proxy filing - Filings